Pharmaceuticals

Parathyroid Disease Treatment Market 2026–2030: Forecasting Business Opportunities Ahead

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the parathyroid disease treatment market from 2026–2035 with trusted insights from The Business Research Company

How much is the Parathyroid Disease Treatment Market valued at in 2026, and what valuation is forecast for 2030?

The parathyroid disease treatment market size has experienced strong growth in recent years. It is anticipated to expand from $2.37 billion in 2025 to $2.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.2%. The historical expansion of this market can be attributed to factors such as the rising prevalence of hyperparathyroidism, limited awareness of parathyroid disorders, dependence on conventional hormone replacement therapy, a lack of advanced surgical interventions, and constrained hospital pharmacy infrastructure.

The parathyroid disease treatment market is projected to experience significant expansion in the coming years. This market is forecast to reach $3.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. Several factors are expected to drive this growth during the forecast period, including a rising demand for calcimimetics and bisphosphonates, progress in parathyroid imaging and diagnostics, the expansion of homecare and telemedicine options, regulatory backing for precision medicine, and the proliferation of specialty centers dedicated to endocrine disorders. Key trends anticipated during the forecast period involve the wider uptake of calcimimetics and bisphosphonates, an increasing inclination towards parenteral administration instead of oral methods for severe conditions, the enlargement of hospital and specialized care environments, an intensified focus on personalized hormone replacement therapies, and the incorporation of lifestyle and nutritional adjustments into treatment strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25866&type=smp

What Drivers Are Influencing The Growth Of The Parathyroid Disease Treatment Market?

The increasing incidence of chronic kidney disease (CKD) is anticipated to fuel the expansion of the parathyroid disease treatment market moving forward. Chronic kidney disease is a long-term ailment characterized by the gradual decline of kidney function, leading to mineral imbalances, including calcium and phosphorus. The escalating presence of chronic kidney disease (CKD) is largely attributable to the rising frequency of diabetes, as persistently high blood sugar levels can gradually impair the kidneys’ filtering units, resulting in diabetic nephropathy. Treatment for parathyroid disease plays a vital role in managing chronic kidney disease (CKD) by addressing secondary hyperparathyroidism, a frequent complication in advanced CKD that disturbs calcium and phosphorus equilibrium, contributes to bone disease, and promotes vascular calcification. For instance, in May 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, it was estimated that more than one in seven adults in the US, equating to approximately 35.5 million people or roughly 14%, had chronic kidney disease in 2023, and nearly 90% of those affected were unaware of their condition. Thus, the growing prevalence of chronic kidney disease is driving the development of the parathyroid disease treatment market.

What Segments Are Included Within The Parathyroid Disease Treatment Market?

The parathyroid disease treatment market covered in this report is segmented –

1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments

2) By Route Of Administration: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid

3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin

4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)

5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions

Which Trends Are Influencing The Performance And Direction Of The Parathyroid Disease Treatment Market?

Leading companies in the parathyroid disease treatment market are concentrating on creating novel products, such as parathyroid hormone prodrugs, to enhance calcium control and lower the frequency of doses for patients with hypoparathyroidism. These parathyroid hormone (PTH) prodrugs are inactive substances that transform into active PTH within the body, aiding in calcium and phosphate balance. An example of this innovation is Ascendis Pharma A/S, a biopharmaceutical firm based in Denmark, which obtained US Food and Drug Administration (FDA) approval in August 2024 for YORVIPATH (palopegteriparatide), a prodrug of parathyroid hormone (PTH[1-34]), intended for treating chronic hypoparathyroidism in adults. This once-daily treatment ensures continuous parathyroid hormone exposure over 24 hours, offering a direct solution to the underlying hormone deficiency, unlike traditional calcium and vitamin D supplementation. The FDA’s decision to approve YORVIPATH emphasizes the growing importance of advanced hormone replacement therapies, designed to improve patient adherence and achieve superior clinical results for individuals with parathyroid conditions.

Who Are The Prominent Global Companies Shaping The Parathyroid Disease Treatment Market Landscape?

Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Kyowa Kirin Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Vidasym Inc., Rani Therapeutics LLC, Pathalys Pharma Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/parathyroid-disease-treatment-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Parathyroid Disease Treatment Market?

Asia-Pacific was the largest region in the parathyroid disease treatment market in 2025. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Parathyroid Disease Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25866&type=smp

Browse Through More Reports Similar to the Global Parathyroid Disease Treatment Market 2026, By The Business Research Company

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Anti Thyroid Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795